Cannabinoid Biosciences Inc. (CBDZ) Crowdfunding Fundraising Is a Success So Far
CBDZ has been able to attract 178 investors to raise about $4.6 million in pre-launch funding.
LOS ANGELES, June 26, 2019 /PRNewswire-PRWeb/ -- Cannabinoid Biosciences Inc. (CBDZ) is a California based biopharmaceutical company whose mission is to revolutionize and standardize the pharmaceuticals and non-pharmaceutical CBD products across the CBD market in the United States of America and to some extent, globally. CBDZ controls the production and distribution of verities of consumer cannabidiol (CBD) formulation under private brands in the United States. CBDZ's goal is to bring standardization to the CBD industry, the same way that John D Rockefeller's Standard Oil brought standardization to crude refining in the United States in the nineteenth century. CBDZ's products include tinctures, capsules, gummies, bath bombs, vape oils, topical creams, and animal treats and oils. The company sells its products directly to consumers through the company Website, as well as non-affiliated stores in 40 states. The company was founded in 2014 and is based in Los Angeles, California. https://cbdxfund.com/invest/
CBDZ has been qualified by the United States Securities and Exchange Commission (SEC) to raise through Regulation A+, the company is set to revolutionize and standard the processes and innovation of CBD products nationwide. See. https://www.sec.gov/Archives/edgar/data/1760319/000176031919000010/cannabinoidbiosciencesregaf2.htm. See also. https://cbdxfund.com/faq/
Although CBDZ Regulation A+ crowdfunding campaign has not been officially launched, CBDZ has been able to attract 178 investors to raise about $4.6 million in pre-launch funding. See. https://www.crowdfunder.com/cbdxfund/deal_card
Competition: Cannabinoid Biosciences, Inc.'s main competition in the biopharma arena is GW Pharmaceuticals plc. GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of glioblastoma, neonatal hypoxic-ischemic encephalopathy, and schizophrenia. Further, the company has license and development agreements with Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United Kingdom, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
SOURCE Cannabinoid Biosciences Inc.
Share this article